Physician profile
Brooke E Brander
NPI 1083838239
$6,179.57
in general payments reported to CMS, 2019-2025
65 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $1,288 · 2021: $560 · 2022: $513 · 2023: $579 · 2024: $1,350 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.03 |
| Education | $180.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $419.15 | 2019-2025 | Tecvayli, Talvey, Carvykti |
| Janssen Pharmaceuticals, INC | $415.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $413.01 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Daiichi Sankyo INC. | $399.29 | 2020-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $388.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $368.52 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $287.04 | 2019-2025 | |
| Amgen INC. | $279.62 | 2019-2022 | |
| Pfizer INC. | $233.42 | 2023-2025 | |
| Eisai INC. | $213.86 | 2019-2024 | |
| Gilead Sciences, INC. | $205.68 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $201.19 | 2019-2025 | Fruzaqla, Vonvendi |
| Puma Biotechnology, INC. | $191.48 | 2019-2025 | |
| Astellas Pharma US INC | $155.12 | 2019-2024 | Xtandi, Xospata |
| Glaxosmithkline, LLC. | $122.36 | 2020-2025 | Ojjaara |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Brander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.